NYSE
273.20USD
-2.00 (-0.73%)
We have scored 102 news catalysts on Johnson & Johnson (JNJ) over the past 12 months. The biggest single-day move next to one of them came Oct 13, 2026, when JNJ closed −5.7%: “Dow opens higher as US stocks fall on chip selloff and mixed bank earnings”. Coverage across the window leans positive (average ticker sentiment +0.39). Most of the impact sits in sector healthcare and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
657.7B
P/E
—
EPS
—
Beta
0.23
52W range
185.12-282.02
Day range
273.17–282.00
Open
280.91
Prev close
275.20
Volume
9M
Avg volume
7.3M
Dividend
5.28
IPO
1962-01-02
Analysts publish price targets on JNJ, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
19 analyst price targets from $260 to $320
as of 2026-09-03
The market is within 2% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Johnson & Johnson — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Johnson & Johnson, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for JNJ: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
The price at $273 sits within 2% of the median published target of $282 and at the 37th percentile of the model spread, meaning the market broadly endorses the consensus but explicitly rejects the 16% upside envisioned by the lone bull case.
What the disagreement turns on
Can Innovative Medicine and MedTech collectively accelerate revenue growth from the delivered 6% toward the 13.1% the price requires, and the available unit volume data can track whether that acceleration is actually happening.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $275 on 2026-09-03 — 59 days ago.
